▶주메뉴 바로가기
▶본문 바로가기
Celltrion announced on Dec. 9 that it has disclosed its biosimilar Truxima’s results of phase 3 clinical trial at the 2019 annual meeting of the American Society of Hematology last week. “The clinical trials were conducted among patients in European countries including Germany, Spain and Russia ...
South Korea’s nonlife insurance firms saw their combined net profit drop 24.6 percent in the first nine months of 2019 from a year earlier, mainly due to increased losses stemming from their long-term insurance and auto insurance businesses, data showed Dec. 2. Nonlife insurance firms operatin...
SK Chemical on Nov. 27 announced that its SID 710, a patch-type medication that aims to treat people with Alzheimer’s disease has won sales approval from the US Food and Drug Administration. The patch has been sold under the name Wondron Patch, a generic version of Novartis’ Exelon Patch for Alz...
South Korean biopharmaceutical firm Celltrion said Nov. 26 that its drug Remsima SC for the treatment of autoimmune diseases has won sales approval in Europe. The European Medicines Agency has given the green light to Celltrion’s application to sell the subcutaneous version of Remsima, a biosi...
South Korean drug firm SK Biopharmaceuticals is expected to raise at least 5 trillion won ($4.25 billion) through a planned share sale, analysts said Nov. 25. The company said that XCOPRI has won approval from the US Food and Drug Administration for the treatment of partial-onset seizures in ad...
South Korean biotech firm Bridge Biotherapeutics CEO Lee Jung-kyu announced Nov. 22 that the company plans to expand further after going public in December. The company expects to be listed on the second-tier Kosdaq market. “We hope to become a global biotech company by advancing both our busine...
SK Biopharmaceuticals said Nov. 22 its anti-epileptic drug has won approval from the US Food and Drug Administration. The company said the FDA granted approval of XCOPRI, or cenobamate tablets, for the treatment of partial-onset seizures in adults. This is the first time a South Korean phar...
South Korea’s Samsung Bioepis said Nov. 20 that the US Food and Drug Administration has started reviewing its application for sales of SB8, a proposed biosimilar referencing Avastin. Samsung Group’s biosimilar development unit had applied for FDA’s marketing approval in September. Avastin is a...
SK Biopharm announced on Nov. 18 that its narcolepsy drug Sunosi received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Narcolepsy is a debilitating neurological disorder characterized by excessive sleepiness. According to SK Biopha...
Celltrion Pharm, the generic arm of Celltrion, announced Nov. 14 that its sales jumped 36.6 percent in the third quarter from a year earlier to 47.43 billion won ($40.7 million). The South Korean company added that its operating profit and net profit moved into the black this quarter, respectively...
Samsung Biologics announced Nov. 14 that it has received 27001 security certification from the Geneva-based International Organization for Standardization. The company emphasized that it is the first contract manufacturing organization to obtain ISO 27001 certification. German Ambassador to South...
Korean biotech firm Hugel announced Nov. 12 that its operating profit jumped 225 percent in the third quarter from a year earlier to 18.2 billion won ($15.57 million). Its sales increased by 46.4 percent to 51.1 billion won. Hugel said its overall profit improved recently due to the sales growth ...
GOTTINGEN, Germany -- Behind the market expansion of Samsung’s biologics business is 149-year-old Sartorius, a German firm that has helped it grow rapidly. Founded in 1870, the German company supplies single-use bags and membrane filters on top of many others that are necessary for biopharmaceuti...
South Korean pharmaceutical firm Samsung Bioepis said Nov. 7 it has entered into a new commercialization agreement worth $370 million with US partner Biogen. Under the partnership, Biogen will be responsible of marketing and sales of Samsung Bioepis’ two ophthalmology biosimilars -- SB11 and S...
Celltrion announced on Nov. 5 that it will start phase 3 clinical trials of its patch-type donepezil, a medication that aims to treat people with Alzheimer’s disease, jointly with local drugmaker Icure. Established in 2000, Icure is a Kosdaq-listed firm that possesses more than 50 patents related...
Korean builders nervous about possible setbacks in Middle East
HD Hyundai chair receives honorary doctorate from HUFS
SC Bank Korea offers special interest rate for new members
Hyundai-Kia marks 40 years of partnerships with over 100 suppliers: report
Samsung expected to introduce new Exynos processor in next Galaxy series
Woori, KB ink QR code payment partnership with Cambodia